Literature DB >> 22142351

Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).

Niren K Shah1, Steven M Smith, Wilmer W Nichols, Margaret C Lo, Umna Ashfaq, Priya Satish, Julie A Johnson, Benjamin J Epstein.   

Abstract

Blood pressure (BP) characteristics, such as central aortic pressure and arterial stiffness, independently predict cardiovascular events. The effects of pharmacologically dissimilar β-blockers on these properties have not been fully elucidated. Patients with essential hypertension and without significant concomitant cardiovascular disease were randomly assigned to controlled-release carvedilol, force-titrated to 80 mg (n=22), or atenolol, force-titrated to 100 mg (n=19); each was given once daily for 4 weeks. Baseline characteristics were similar. At the end of week 4, atenolol and carvedilol reduced central and brachial systolic and diastolic BP to a similar extent. Central augmentation index was increased in atenolol-treated patients but not carvedilol-treated patients (atenolol 4.47% vs carvedilol -0.68%; P=.04). Mean augmented central aortic pressure increased slightly during atenolol treatment (+1.1 mm Hg) but decreased slightly during carvedilol treatment (-1.1 mm Hg), although the difference in these changes was not statistically significant (P=.23). Pulse pressure amplification was reduced more with atenolol at week 4 (atenolol -10.7% vs carvedilol -1.8%; P=.02). Therefore, we conclude that carvedilol results in more favorable pulse pressure amplification and augmentation index by increasing arterial compliance and reducing the magnitude of wave reflection, respectively, compared with atenolol.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22142351      PMCID: PMC8108766          DOI: 10.1111/j.1751-7176.2011.00549.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  38 in total

1.  The influence of heart rate on augmentation index and central arterial pressure in humans.

Authors:  I B Wilkinson; H MacCallum; L Flint; J R Cockcroft; D E Newby; D J Webb
Journal:  J Physiol       Date:  2000-05-15       Impact factor: 5.182

Review 2.  Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.

Authors:  Angelo M Carella; Giuseppe Antonucci; Matteo Conte; Michele Di Pumpo; Armando Giancola; Elisabetta Antonucci
Journal:  Curr Diabetes Rev       Date:  2010-07

3.  Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.

Authors:  Jorge Polónia; Loide Barbosa; José Alberto Silva; Susana Bertoquini
Journal:  Blood Press Monit       Date:  2010-10       Impact factor: 1.444

4.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

5.  Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.

Authors:  Nadia Khan; Finlay A McAlister
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

6.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

Review 7.  Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data.

Authors:  Alberto P Avolio; Luc M Van Bortel; Pierre Boutouyrie; John R Cockcroft; Carmel M McEniery; Athanase D Protogerou; Mary J Roman; Michel E Safar; Patrick Segers; Harold Smulyan
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

8.  Controlled-release carvedilol in the treatment of essential hypertension.

Authors:  Michael A Weber; Domenic A Sica; Elizabeth A Tarka; Malini Iyengar; Richard Fleck; George L Bakris
Journal:  Am J Cardiol       Date:  2006-08-28       Impact factor: 2.778

9.  The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients.

Authors:  Gisli Jonsson; Michael Abdelnoor; Ingebjorg Seljeflot; Harald Arnesen; Arne T Hostmark; Sverre E Kjeldsen; Ingrid Os; Arne S Westheim
Journal:  J Cardiovasc Pharmacol       Date:  2007-01       Impact factor: 3.105

10.  Atenolol in hypertension: is it a wise choice?

Authors:  Bo Carlberg; Ola Samuelsson; Lars Hjalmar Lindholm
Journal:  Lancet       Date:  2004 Nov 6-12       Impact factor: 79.321

View more
  9 in total

Review 1.  Impact of Antihypertensive Agents on Central Systolic Blood Pressure and Augmentation Index: A Meta-Analysis.

Authors:  Tracey J McGaughey; Emily A Fletcher; Sachin A Shah
Journal:  Am J Hypertens       Date:  2015-08-19       Impact factor: 2.689

2.  The effects of acute beta-adrenergic blockade on aortic wave reflection in postmenopausal women.

Authors:  Darren P Casey; Timothy B Curry; Nisha Charkoudian; Michael J Joyner; Emma C Hart
Journal:  Am J Hypertens       Date:  2013-01-11       Impact factor: 2.689

Review 3.  Heart rate and blood pressure: any possible implications for management of hypertension?

Authors:  Scott Reule; Paul E Drawz
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

Review 4.  Central blood pressure: current evidence and clinical importance.

Authors:  Carmel M McEniery; John R Cockcroft; Mary J Roman; Stanley S Franklin; Ian B Wilkinson
Journal:  Eur Heart J       Date:  2014-01-23       Impact factor: 29.983

5.  The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.

Authors:  Péter Studinger; Ádám G Tabák; Chen-Huan Chen; Paolo Salvi; Taha E H Othmane; Péter Torzsa; Judit Kapocsi; Bertalan C Fekete; András Tislér
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-10-04       Impact factor: 3.738

6.  Electrocardiogram derived QRS duration associations with elevated central aortic systolic pressure (CASP) in a rural Australian population.

Authors:  Yvonne Yin Leng Lee; Paul Reidler; Herbert Jelinek; Yung Seng Lee; Yuling Zhou; Brett D Hambly; Joel McCabe; Slade Matthews; Honghong Ke; Hassan Assareh; Craig S McLachlan
Journal:  Clin Hypertens       Date:  2016-02-16

7.  I Luso-Brazilian Positioning on Central Arterial Pressure.

Authors:  Andréa A Brandão; Celso Amodeo; Cristina Alcântara; Eduardo Barbosa; Fernando Nobre; Fernando Pinto; José Fernando Vilela-Martin; José Mesquita Bastos; Juan Carlos Yugar-Toledo; Marco Antônio Mota-Gomes; Mario Fritsch Toros Neves; Marcus Vinícius Bolívar Malachias; Manuel de Carvalho Rodrigues; Oswaldo Passarelli; Paulo César B Veiga Jardim; Pedro Guimarães Cunha; Rui Póvoa; Teresa Fonseca; Vitor Paixão Dias; Weimar Sebba Barroso; Wille Oigman
Journal:  Arq Bras Cardiol       Date:  2017-02-13       Impact factor: 2.000

8.  B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease.

Authors:  Dipak Kotecha; Marcus D Flather; Dan Atar; Peter Collins; John Pepper; Elizabeth Jenkins; Christopher M Reid; David Eccleston
Journal:  BMC Med       Date:  2019-04-03       Impact factor: 8.775

9.  Real time 3D echocardiography (RT3D) for assessment of ventricular and vascular function in hypertensive and heart failure patients.

Authors:  Maria Chiara Scali; Massimiliano Basso; Alfredo Gandolfo; Tonino Bombardini; Paolo Bellotti; Rosa Sicari
Journal:  Cardiovasc Ultrasound       Date:  2012-06-28       Impact factor: 2.062

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.